Notably, in relapsed or refractory ALL, FLT3 inhibition may restore chemosensitivity in cases harboring activating mutations, making FLT3 a potentially actionable target in selected patients [34,36]. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.